<DOC>
	<DOCNO>NCT01586858</DOCNO>
	<brief_summary>Rituximab first drug approve United States Food Drug Administration ( FDA ) treatment patient granulomatosis polyangiitis ( Wegener 's granulomatosis ) microscopic polyangiitis . Because relatively new medication , long-term safety efficacy drug yet clear . This study propose follow patient enrol RAVE study determine treatment rituximab influence long-term outcome .</brief_summary>
	<brief_title>Rituximab ANCA-associated Vasculitis ( RAVE ) Long-Term Follow-Up Study</brief_title>
	<detailed_description />
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
	<mesh_term>Microscopic Polyangiitis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Enrollment RAVE trial 2 . Completion RAVE Common Closeout Date visit 3 . Informed consent 1 . Refusal participate 2 . Inability comply standardofcare , include routine clinical visit test .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Vasculitis</keyword>
	<keyword>ANCA</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Small vessel vasculitis</keyword>
</DOC>